Lawmakers propose pathway for approving biosimilars

A group of lawmakers on Capitol Hill has introduced legislation that establishes a clear pathway for the approval of biosimilars. The bill has already attracted the wide support of a diverse group of lobbyists, including the AARP, health plans and pharmacy benefit managers, who would like to see the price of complex biotech drugs go down. BIO has long been on record that it isn't necessarily opposed to biosimilars--cheaper follow-on versions of branded biotech drugs--but insists that the complexity of biologics requires the FDA to insist on a separate set of expensive studies before any follow-on therapy can be approved. In Europe the EMEA has had a regulatory pathway in place for almost three years.

- read the report on biosimilars from Empire State News

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.